Full text is available at the source.
Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review
Cigarette smoking, type 2 diabetes, and potential treatment with glucagon-like peptide-1 drugs for smokers with diabetes
AI simplified
Abstract
Cigarette smoking in individuals with type 2 diabetes mellitus is associated with twice the likelihood of mortality and negative health outcomes.
- Tobacco use disorder (TUD) significantly contributes to complications in type 2 diabetes mellitus (DM).
- Persons with DM who regularly use tobacco products face increased health risks compared to non-smokers.
- Epidemiological and preclinical biological evidence supports the interconnectedness of TUD and DM.
- Glucagon-like peptide-1 (GLP-1) may serve as a potential treatment target for addressing TUD in smokers with DM.
AI simplified